/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
The drugmaker announces plans to start clinical trials of a formulation that will give it a shot at a space dominated by Eli Lilly and Novo Nordisk’s blockbuster offerings.
The drugmaker announces plans to start clinical trials of a formulation that will give it a shot at a space dominated by Eli Lilly and Novo Nordisk’s blockbuster offerings.
The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.
Quick-commerce apps are likely to run into regulations and poor order volumes as they try to grow this business.
The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.
Quick-commerce apps are likely to run into regulations and poor order volumes as they try to grow this business.
